Physician profile
Michael Patrick Krease
NPI 1003255365
$321,767.75
in general payments reported to CMS, 2019-2025
47 companies · $161K in 2025
The $161K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $1,755 · 2021: $2,922 · 2022: $2,897 · 2023: $3,165 · 2024: $149K · 2025: $161K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $272K · Consulting Fee: $16K · Food and Beverage: $13K · Travel and Lodging: $12K · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $271,818.66 |
| Consulting Fee | $16,159.00 |
| Food and Beverage | $13,290.57 |
| Travel and Lodging | $11,633.94 |
| Education | $196.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $208,249.76 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $61,414.79 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $19,440.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $16,495.86 | 2024-2025 | Voquezna |
| Abbvie INC. | $5,006.44 | 2019-2025 | |
| Janssen Biotech, INC. | $2,707.81 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $1,995.13 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,635.25 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $893.93 | 2019-2025 | |
| Ardelyx, INC. | $600.31 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $468.30 | 2020-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $447.77 | 2019-2023 | Rebyota, Cimzia |
| Celgene Corporation | $392.09 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $303.41 | 2019-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $273.72 | 2019-2024 | Dificid |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $177.60 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $124.74 | 2021 | |
| Intercept Pharmaceuticals, INC. | $110.24 | 2020-2025 | Ocaliva |
| Redhill Biopharma INC. | $104.84 | 2020-2023 | Movantik, Talicia, Aemcolo |
| Csl Behring | $93.69 | 2019-2022 | |
| Lilly USA, LLC | $71.15 | 2025 | Omvoh |
| Fresenius Kabi USA, LLC | $66.53 | 2023-2024 | Idacio |
| Allergan, INC. | $55.08 | 2020 | |
| Mauna Kea Technologies, INC. | $52.66 | 2023 | |
| Nestle Healthcare Nutrition INC. | $52.22 | 2023 | |
| Ucb, INC. | $51.65 | 2019-2020 | |
| Boston Scientific Corporation | $48.28 | 2025 | Compliance Endokit, Watchman Flx |
| Evoke Pharma, INC. | $46.91 | 2022-2025 | |
| Sandoz INC. | $43.91 | 2023-2025 | Hyrimoz |
| Albireo Pharma, INC. | $39.36 | 2024 | Bylvay |
| Amgen INC. | $38.37 | 2021-2023 | Avsola, Amjevita |
| Novo Nordisk INC | $37.65 | 2023-2025 | Wegovy |
| Braintree Laboratories, INC. | $36.20 | 2023-2024 | Suflave |
| Celltrion USA INC. | $36.09 | 2024-2025 | Zymfentra, Vegzelma |
| Aimmune Therapeutics, INC. | $24.75 | 2024 | |
| Organon LLC | $22.25 | 2021-2023 | Renflexis |
| Daiichi Sankyo INC. | $20.67 | 2022 | |
| Vivus LLC | $18.98 | 2025 | Pancreaze |
| Shionogi INC | $16.77 | 2019 | |
| Shire North American Group INC | $16.16 | 2019 | |
| Axonics, INC. | $14.01 | 2022 | |
| Medtronic, INC. | $12.87 | 2023 | Gi Genius |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Krease listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.